Lyell Immunopharma Inc (LYEL) concluded trading on Thursday at a closing price of $0.58, with 3.33 million shares of worth about $1.93 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -57.52% during that period and on February 13, 2025 the price saw a gain of about 8.42%. Currently the company’s common shares owned by public are about 256.56M shares, out of which, 150.78M shares are available for trading.
Stock saw a price change of -1.52% in past 5 days and over the past one month there was a price change of 1.31%. Year-to-date (YTD), LYEL shares are showing a performance of -9.06% which decreased to -69.84% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.51 but also hit the highest price of $3.26 during that period. The average intraday trading volume for Lyell Immunopharma Inc shares is 1.23 million. The stock is currently trading -0.05% below its 20-day simple moving average (SMA20), while that difference is down -12.11% for SMA50 and it goes to -58.15% lower than SMA200.
Lyell Immunopharma Inc (NASDAQ: LYEL) currently have 256.56M outstanding shares and institutions hold larger chunk of about 21.31% of that.
The stock has a current market capitalization of $170.04M and its 3Y-monthly beta is at -0.36. It has posted earnings per share of -$0.80 in the same period. It has Quick Ratio of 13.43 while making debt-to-equity ratio of 0.11. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for LYEL, volatility over the week remained 9.26% while standing at 8.50% over the month.
Stock’s fiscal year EPS is expected to rise by 21.51% while it is estimated to increase by 4.79% in next year. EPS is likely to grow at an annualized rate of 17.62% for next 5-years, compared to annual growth of -15.28% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by BofA Securities on October 30, 2024 offering an Underperform rating for the stock and assigned a target price range of between $6 and $1 to it. Coverage by H.C. Wainwright stated Lyell Immunopharma Inc (LYEL) stock as a Neutral in their note to investors on June 27, 2024, suggesting a price target of $1 for the stock. On August 28, 2023, JP Morgan Downgrade their recommendations, while on November 14, 2022, Morgan Stanley Downgrade their ratings for the stock with a price target of $7. Stock get a Neutral rating from Goldman on November 11, 2022.
